The Biotech That Figured Out How To Make Oxygen Profitable

A few months ago, I was catching up with a former colleague over coffee when he casually mentioned something that nearly made me spit out my latte.

“You know this little pill I take twice a day?” he said, tapping his chest. “It probably costs more than most people’s rent. Maybe their mortgage too.”

He was talking about Trikafta, Vertex’s blockbuster cystic fibrosis treatment that clocks in at a cool $300,000 annually.

Before I could wrap my head around that number, he added the kicker: “But my doctor said my lung function has improved 18% since I started taking it. Hard to put a price on actually being able to breathe, you know?”

That’s when it hit me. Vertex Pharmaceuticals (VRTX) hasn’t just created a drug — they’ve essentially figured out how to monetize oxygen.

And right now, with the stock drifting from $520 down to the $430s, it might be time to pay attention to this particular feat of capitalist ingenuity.

Here’s what makes Vertex absolutely fascinating from an investment perspective: they’ve built what amounts to the world’s most expensive subscription service, except canceling isn’t really an option.

They own 95% of the cystic fibrosis market, pulling in over $10 billion annually from roughly 70,000 patients who have exactly zero viable alternatives. When your customer’s choice is “pay up or slowly suffocate,” customer retention becomes remarkably predictable.

This isn’t some discretionary purchase that gets cut during economic downturns. This is “I need this to live” medicine, backed by patent protection through 2039.

But here’s where the story gets really interesting, and where most investors are missing the plot.

Vertex management isn’t content to just milk their CF cash cow until it runs dry. They’re using that $10 billion annual windfall to fund what’s essentially the world’s most expensive venture capital experiment, betting on moonshot therapies across diabetes, pain management, and gene therapy.

Think about this for a second: they’ve taken the most predictable revenue stream in biotech and turned it into a funding mechanism for high-risk, high-reward bets in massive markets.

It’s like if Netflix (NFLX) decided to use their subscription revenue to fund space exploration — audacious, potentially brilliant, and definitely not boring.

The diversification efforts are where things get spicy.

Their gene therapy for sickle cell disease is approved but rolling out slower than a government DMV line.

Their pain management program? Well, let’s just say their recent chronic pain trials showed “no separation between drug and placebo,” which is biotech speak for “whoops, back to the drawing board.”

Meanwhile, competitors like Tris Pharma are out there posting phase 3 data showing their pain drugs actually outperform standard opioids.

Vertex was first to market with their non-opioid pain treatment Journavx, but being first with mediocre results in a competitive race is like being first to show up at a party that turns out to be terrible.

This creates a delicious valuation puzzle that most analysts are approaching all wrong.

Vertex trades at 24x forward earnings while peers like Gilead (GILD) and Amgen (AMGN) sit around 13x. The market is essentially saying, “We’ll pay double the normal biotech multiple because we believe in your ability to not screw up spectacularly.”

But here’s the math that makes this whole thing make sense: strip out the CF business — growing conservatively at 8% annually — and it probably justifies about $69 billion of their current $110 billion market cap.

That leaves $41 billion, roughly 38% of the company’s value, riding entirely on whether their pipeline experiments actually work.

For a company with two approved non-CF treatments and five more shots on goal by 2028, you’re either getting a bargain or overpaying dramatically. There’s not much middle ground in biotech.

What makes the current setup particularly intriguing is the timing.

Over the next 18 months, Vertex has multiple binary events that could either validate that $41 billion pipeline bet or send it crashing back to earth.

Diabetes trial results, expanded pain indications, international approvals — each one a mini-lottery ticket that could justify the current valuation or obliterate it.

The risk, obviously, is that biotech graveyards are littered with companies that had one brilliant success and used the profits to fund a dozen expensive failures.

The transition from dominating rare genetic diseases to competing in mass markets like diabetes and chronic pain is like going from playing chess to playing football — completely different skill sets, completely different rules.

But here’s what I find genuinely compelling about Vertex’s position: they don’t need to hit grand slams on every pipeline program. They just need to not strike out completely.

With their CF fortress generating consistent free cash flow and management that’s proven they can navigate the FDA’s regulatory maze, the downside seems reasonably well-protected.

The current pullback feels more like broader biotech rotation than any fundamental deterioration in Vertex’s prospects. When quality companies with predictable cash flows and legitimate growth optionality go on sale, that’s usually when interesting opportunities emerge.

What you’re buying with Vertex isn’t just another biotech stock — you’re buying a regulated utility that happens to be running a venture capital fund on the side. The utility part keeps paying the bills while the VC part swings for the fences.

Besides, if you’re going to corner a market, might as well pick something people can’t live without.